The pharmacokinetics of etanercept in healthy volunteers

被引:1
|
作者
Korth-Bradley, JM
Rubin, AS
Hanna, RK
Simcoe, DK
Lebsack, ME
机构
[1] Wyeth Ayerst Res, Clin Pharmacokinet, Philadelphia, PA 19101 USA
[2] Immunex Corp, Biometr, Seattle, WA 98101 USA
[3] Immunex Corp, Analyt Resources Dept, Seattle, WA 98101 USA
关键词
phamacokinetics; etanercept;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers, METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations. RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/- 98 mg.h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours. CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [21] Etanercept in psoriasis
    Papp, KA
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) : 2139 - 2146
  • [22] Etanercept biosimilars
    Azevedo, Valderilio F.
    Galli, Nathalia
    Kleinfelder, Alais
    D'Ippolito, Julia
    Urbano, Paulo C. M.
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (02) : 197 - 209
  • [23] Etanercept biosimilars
    Valderilio F. Azevedo
    Nathalia Galli
    Alais Kleinfelder
    Julia D’Ippolito
    Paulo C. M. Urbano
    Rheumatology International, 2015, 35 : 197 - 209
  • [24] Etanercept and infections
    Bertouch, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) : 1209 - 1210
  • [25] Etanercept and pregnancy
    Otermin, I.
    Elizondo, G.
    Zabaleta, J.
    Amigot, A.
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2007, 30 (03) : 491 - 493
  • [26] Etanercept and infections
    Ribera, M.
    Leal, L.
    Luelmo, J.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 70 - 76
  • [27] Etanercept and neoplasms
    Garcia-Rabasco, A.
    Sanchez-Carazo, J. L.
    Esteve, A.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 88 - 96
  • [28] Etanercept in juvenile psoriasis [Etanercept in dertherapie der juvenilen psoriasis]
    Beikert F.C.
    Augustin M.
    Radtke M.A.
    Der Hautarzt, 2012, 63 (5): : 406 - 410
  • [29] Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia
    Haroon, Muhammad
    Daly, Mary
    Harney, Sinead
    CLINICAL RHEUMATOLOGY, 2012, 31 (01) : 151 - 155
  • [30] Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia
    Muhammad Haroon
    Mary Daly
    Sinead Harney
    Clinical Rheumatology, 2012, 31 : 151 - 155